Clinical Trials Sponsored by Pharmbio Korea Inc.

Total 155 results

Korea University Guro Hospital
Pharmbio Korea Inc.

Not yet recruiting

Intravenous Iron Infusion on Chemotherapy-induced Anemia

Colon Cancer | Chemotherapeutic-Induced Anemia
Pharmbio Korea Co., Ltd.

Recruiting

A Study to Evaluate Safety and Efficacy of PBK_M2101

Colonic Diseases | Digestive System Disease | Gastrointestinal Disease | Intestinal Disease

Korea, Republic of
Pharmbio Korea Co., Ltd.

Not yet recruiting

Study to Evaluate the Efficacy and Safety of PBK_L2201 in Postmenopausal Women With Osteoporosis

Osteoporosis

Korea, Republic of
Pharmbio Korea Co., Ltd.

Recruiting

Study of PBK_L1704 for the Treatment of Moderate to Severe Acute Pain After Bunionectomy in South Korea

Acute Pain

Korea, Republic of
Pharmbio Korea Co., Ltd.

Not yet recruiting

Comparison for Efficacy and Safety of Bowel Preparation Between Oral Sulfate Table and 2L-polyethylene Glycol/Ascorbate in Elderly

Intestinal Disease | Colonic Disease
Pharmbio Korea Co., Ltd.

Completed

Pharmacokinetics and Safety of PBK-1801 After Single Oral Administration in Healthy Korean Women

Healthy Volunteer

Korea, Republic of
Pharmbio Korea Co., Ltd.

Completed

Safety and Efficacy of PBK-1701TC for Bowel Cleansing Before Colonoscopy

Colonic Diseases | Digestive System Disease | Gastrointestinal Disease | Intestinal Disease

Korea, Republic of
Pharmbio Korea Co., Ltd.

Completed

Effect of Probiotic Lactobacilli (Lacidofil Cap®) for the Prevention of Antibiotic-Associated Diarrhea

Pulmonary Infection | Antibiotics Associated Colitis

Korea, Republic of
Korea University Anam Hospital
Pharmbio Korea Co., Ltd.

Unknown

The Effect of Somatostatin for Treatment of Post Hepatectomy Liver Failure (PHLF)

Liver Failure

Korea, Republic of
National Cancer Center, Korea
Pharmbio Korea Co., Ltd.

Completed

Pancreatic Enzyme Supplementation in Patients With Unresectable Pancreatic Cancer (PESUP)

Pancreatic Cancer

Korea, Republic of
DongGuk University
Pharmbio Korea Co., Ltd.

Completed

Effect of Rowachol on Prevention of Postcholecystectomy Syndrome

Postcholecystectomy Syndrome

Korea, Republic of
Seoul National University Hospital
Pharmbio Korea

Unknown

Efficacy of Nefopam and Morphine in Balanced Analgesia for Acute Ureteric Colic

Renal Colic

Korea, Republic of
Seoul National University Hospital
Pharmbio Korea

Completed

Effects of Continuous Infusion of Intravenous Nefopam on Postoperative Pain and Opioid Consumption After VATS

Postoperative Pain

Korea, Republic of
Seoul National University Hospital
Pharmbio Korea Co., Ltd.

Completed

Nefopam/Fentanyl Postoperative Intravenous Patient-Controlled-Analgesia

Laparotomy
Seoul National University Hospital
Pharmbio Korea Co., Ltd.

Completed

The Effect of Dexmedetomidine on Postoperative Analgesia

Colon Cancer, Rectal Cancer

Korea, Republic of
Seoul National University Hospital
Pharmbio Korea Co., Ltd.

Completed

The Effects of High Dose Pancreatic Enzyme Replacement Therapy After Pancreatoduodenectomy

Pancreaticoduodenectomy

Korea, Republic of
Eisai Inc.
PharmaBio Development Inc.

Terminated

Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer

Bladder Cancer

United Kingdom, Netherlands, Spain, Germany, United States, Ukraine
Eisai Inc.
PharmaBio Development Inc.

Completed

E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck

Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck

United States, Korea, Republic of, Ukraine, United Kingdom
Eisai Inc.
PharmaBio Development Inc.

Terminated

Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer

Rectal Cancer | Colon Cancer

Argentina, Russian Federation, United States, Australia, Brazil, Ukraine
Eisai Inc.
PharmaBio Development Inc.

Terminated

E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125

Ovarian Cancer

United States
Eisai Inc.
PharmaBio Development Inc.

Completed

Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma

Stage IV Melanoma | Stage IIIC Melanoma

United States
Eisai Inc.
PharmaBio Development Inc.

Completed

E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Participants With Hepatocellular Carcinoma

Hepatocellular Carcinoma

Belgium, Italy, Spain, United States, Ukraine, United Kingdom
Bo-In Lee
Pharmbio Korea Co., Ltd.

Completed

Oral Sulfate Solution (SUPREP) Versus Polyethylene Glycol (PEG) Plus Ascorbic Acid

Cathartic Colon

Korea, Republic of
PhaseBio Pharmaceuticals Inc.

Terminated

Phase 2 Study to Assess Safety, Tolerability and Efficacy of Once Weekly SC Pemziviptadil (PB1046) in Subjects With Symptomatic PAH (VIP)

Pulmonary Arterial Hypertension

United States
PhaseBio Pharmaceuticals Inc.

Completed

A Study to Assess the Safety, Tolerability, and Hemodynamic Response of PB1046 in Subjects With PAH

Pulmonary Arterial Hypertension

United States
PhaseBio Pharmaceuticals Inc.

Completed

Study to Evaluate the Safety, Tolerability, PK, and PD of PB2452 in Healthy Volunteers

Healthy

United States
PhaseBio Pharmaceuticals Inc.

Completed

Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM

Type 2 Diabetes Mellitus

United States
PhaseBio Pharmaceuticals Inc.

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response of Vasomera (PB1046) Injection Following a Single Subcutaneous Dose in Subjects With Stage 1 or 2 Essential Hypertension

Essential Hypertension

United States
PhaseBio Pharmaceuticals Inc.

Completed

Pharmacokinetic Profile of Two Formulations of PB1023 Following Single Subcutaneous Injection in Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States
PhaseBio Pharmaceuticals Inc.

Completed

Study to Assess the Safety, Tolerability and PK/PD After 4 Weekly SC Injections of PB1046 in Subjects With Stable HFrEF

Heart Failure

United States
PhaseBio Pharmaceuticals Inc.

Terminated

Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS). (VANGARD)

Pneumonia | Respiratory Failure | Respiratory Insufficiency | COVID 19 | Acute Respiratory Distress Syndrome | SARS-CoV-2 | Coronavirus | Cytokine Storm | Pulmonary Edema | Cardiac Event | Respiratory Complication | Cardiac Dysfunction | Hypoxemic Respiratory Failure | Hypoxic Respiratory Failure | Cardiac Failure | Cardiac... and other conditions

United States
PhaseBio Pharmaceuticals Inc.

Completed

Study to Assess the Safety, Tolerability, PK and PD Response of PE0139 Injection in Adult Subjects With T2DM

Type 2 Diabetes Mellitus

United States
PhaseBio Pharmaceuticals Inc.

Completed

Phase 1 Multicenter, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of PE0139 Injection in Adult Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus (T2DM)

United States
PhaseBio Pharmaceuticals Inc.

Completed

Phase 1, Randomized, Double-Blind, Placebo-Controlled Exploratory Study That Will Assess the Safety, Tolerability, Pharmacokinetics and Hemodynamic Response to a Single 30 Minute Intravenous Infusion of Vasomera™ (PB1046) in Adult Subjects With Stage 1 or 2 Essential Hypertension

Essential Hypertension

United States
PhaseBio Pharmaceuticals Inc.

Terminated

Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) in PAH Subjects Following Completion of Study PB1046-PT-CL-0004 (VIP Extend)

Pulmonary Arterial Hypertension

United States
PhaseBio Pharmaceuticals Inc.

Completed

Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Study to Assess Safety, Tolerability, PK and PD Response of PB1023 Injection Following Single and Multiple SQ Doses in Adults With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States
PhaseBio Pharmaceuticals Inc.

Completed

Pharmacokinetic, Safety/Tolerability Study of a Single SC Dose of PB1023 Injection in Subjects With Normal and Impaired Renal Function

Diabetes Mellitus, Type 2

United States
Inocras Korea Inc.

Recruiting

Whole Genome Sequencing in Breast Cancer (WGS SIT)

Breast Cancer

Korea, Republic of
Earlogic Korea, Inc.

Completed

The Effect of Sound Stimulation on Hearing Ability

Sensorineural Hearing Loss

Korea, Republic of
Earlogic Korea, Inc.

Completed

The Effect of Sound Stimulation on Pure-tone Hearing Threshold

Sensorineural Hearing Loss

United States
Linical Korea
National Cancer Center, Korea; Astellas Pharma Korea, Inc.

Completed

To Evaluate the Efficacy and Safety of ADVAGRAF® After Treatment With a Tacrolimus in New Liver Transplant Recipients (Assign)

Liver Transplantation
Eisai Korea Inc.

Completed

A Study of Pariet to Prevent Gastric and Duodenal Ulcer Associated With Low-aspirin in Korean Participants With a History of Gastric and Duodenal Ulcer

Duodenal Ulcer | Stomach Ulcer

Korea, Republic of
Eisai Korea Inc.

Completed

Open-label, Multi-center Trial of Zonisamide as Adjunctive Therapy in Patients With Uncontrolled Partial Epilepsy

Epilepsy

Korea, Republic of
Eisai Korea Inc.

Completed

Comparative Study of Zonisamide and Carbamazepine as an Initial Monotherapy: Efficacy and Safety Evaluation

Epilepsy

Korea, Republic of
Eisai Korea Inc.

Completed

Alzheimer's Disease Long-term Follow-up Study (ALF Study)

Alzheimer's Disease

Korea, Republic of
Eisai Korea Inc.

Completed

A Study of Fycompa (Perampanel) in Korean Participants

Epilepsy

Korea, Republic of
Eisai Korea Inc.

Completed

Study in Patients With Moderated to Severe Rheumatoid Arthritis Who Have Failed to Combination Therapy of Conventional Disease-modifying Antirheumatic Drugs (cDMARDs) to cDMARD Plus ANti-TNF Versus cDMARDs in Real World (HUMAN)

Arthritis, Rheumatoid

Korea, Republic of
Eisai Korea Inc.

Completed

Study to Observe the Change in Microbiome in Human Derived Sample and the Relation With Clinical Response Before and After the Anti-TNF Treatment in IBD Patients (ETERNITY)

Inflammatory Bowel Disease

Korea, Republic of
Eisai Korea Inc.

Completed

A Plan on Investigation and Collection of Aricept Safety Information With a Dose Increase on Alzheimer's Disease Patients (AID)

Alzheimer's Disease

Korea, Republic of
Eisai Korea Inc.

Completed

Eribulin Mesylate Phase IV Clinical Trial in Korean Patients With Metastatic or Locally Advanced Breast Cancer (ESKIMO)

Breast Cancer | Breast Neoplasms

Korea, Republic of

3

Subscribe